Download MendeleyEngineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies.
Henderson, R., Anasti, K., Manne, K., Stalls, V., Saunders, C., Bililign, Y., Williams, A., Bubphamala, P., Montani, M., Kachhap, S., Li, J., Jaing, C., Newman, A., Cain, D.W., Lu, X., Venkatayogi, S., Berry, M., Wagh, K., Korber, B., Saunders, K.O., Tian, M., Alt, F., Wiehe, K., Acharya, P., Alam, S.M., Haynes, B.F.(2024) Nat Commun 15: 9503-9503
- PubMed: 39489734
- DOI: https://doi.org/10.1038/s41467-024-53120-9
- Primary Citation of Related Structures:
8VGV, 8VGW, 8VH1, 8VH2, 8VH3 - PubMed Abstract:
Vaccine development targeting rapidly evolving pathogens such as HIV-1 requires induction of broadly neutralizing antibodies (bnAbs) with conserved paratopes and mutations, and in some cases, the same Ig-heavy chains. The current trial-and-error search for immunogen modifications that improve selection for specific bnAb mutations is imprecise. Here, to precisely engineer bnAb boosting immunogens, we use molecular dynamics simulations to examine encounter states that form when antibodies collide with the HIV-1 Envelope (Env). By mapping how bnAbs use encounter states to find their bound states, we identify Env mutations predicted to select for specific antibody mutations in two HIV-1 bnAb B cell lineages. The Env mutations encode antibody affinity gains and select for desired antibody mutations in vivo. These results demonstrate proof-of-concept that Env immunogens can be designed to directly select for specific antibody mutations at residue-level precision by vaccination, thus demonstrating the feasibility of sequential bnAb-inducing HIV-1 vaccine design.
- Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
Organizational Affiliation:
